Keler T - Search Results

1

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.

Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A. Borchmann P, et al. Among authors: keler t. Blood. 2003 Nov 15;102(10):3737-42. doi: 10.1182/blood-2003-02-0515. Epub 2003 Jul 24. Blood. 2003. PMID: 12881320 Free article.

2

Development of antibody-targeted vaccines.

Keler T, He L, Graziano RF. Keler T, et al. Curr Opin Mol Ther. 2005 Apr;7(2):157-63. Curr Opin Mol Ther. 2005. PMID: 15844624 Review.

3

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P. Ansell SM, et al. Among authors: keler t. J Clin Oncol. 2007 Jul 1;25(19):2764-9. doi: 10.1200/JCO.2006.07.8972. Epub 2007 May 21. J Clin Oncol. 2007. PMID: 17515574 Clinical Trial.

4

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.

Sundarapandiyan K, Keler T, Behnke D, Engert A, Barth S, Matthey B, Deo YM, Graziano RF. Sundarapandiyan K, et al. Among authors: keler t. J Immunol Methods. 2001 Feb 1;248(1-2):113-23. doi: 10.1016/s0022-1759(00)00347-1. J Immunol Methods. 2001. PMID: 11223073

5

Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.

Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, Graziano RF, Leusen JH, van de Winkel JG, Keler T. Bevaart L, et al. Among authors: keler t. Br J Haematol. 2006 Feb;132(3):317-25. doi: 10.1111/j.1365-2141.2005.05884.x. Br J Haematol. 2006. PMID: 16409296 Free article.

6

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.

Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ. Ramakrishna V, et al. Among authors: keler t. J Immunol. 2004 Mar 1;172(5):2845-52. doi: 10.4049/jimmunol.172.5.2845. J Immunol. 2004. PMID: 14978085

7

Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.

Somasundaram C, Sundarapandiyan K, Keler T, Deo YM, Graziano RF. Somasundaram C, et al. Among authors: keler t. Hum Antibodies. 1999;9(1):47-54. Hum Antibodies. 1999. PMID: 10331185

8

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A. Keler T, et al. J Immunol. 2003 Dec 1;171(11):6251-9. doi: 10.4049/jimmunol.171.11.6251. J Immunol. 2003. PMID: 14634142

9

Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.

Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF. Deo YM, et al. Among authors: keler t. J Immunol. 1998 Feb 15;160(4):1677-86. J Immunol. 1998. PMID: 9469424

10

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.

Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM. Keler T, et al. Cancer Res. 1997 Sep 15;57(18):4008-14. Cancer Res. 1997. PMID: 9307286

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters